Literature DB >> 7665901

Anticoagulant selection influences flow cytometric determination of CD11b upregulation in vivo and ex vivo.

H Repo1, S E Jansson, M Leirisalo-Repo.   

Abstract

We recently devised three-colour flow cytometric assay for evaluating expression of CD11b on neutrophils and monocytes in circulation. Artefactual upregulation of CD11b ex vivo was minimized by cooling blood samples on ice. In this communication we further characterize the method in terms of different anticoagulants. EDTA was less optimal than ACD or heparin because (i) saturating concentrations of CD11b antibody (clone D12) were not achieved with resting cells; (ii) CD11b fluorescence intensity of synovial fluid cells, i.e., in vivo activated cells expressing CD11b at high levels, was significantly lower in EDTA plasma, and (iii) EDTA mediated more cell damage at 37 degrees C, as determined by PI staining. The fluorescence data suggested that D12 antibody binding was dependent on divalent cations. Saturating concentrations in the presence of EDTA in medium were easily obtained with synovial fluid cells and peripheral blood phagocytes activated with chemotactic peptide FMLP, suggesting that cell activation decreased cation concentrations required for D12 antibody binding. Using another CD11b antibody (2MPL19c), whose binding proved to be cation independent, it was shown that CD11b upregulation was not affected by EDTA. ACD was superior to heparin and phenylalanylprolylarginyl chloromethyl ketone (PPACK), a thrombin inhibitor, because cell counts were significantly lower in heparinized samples in cold, and in PPACK-anticoagulated samples treated with LPS at 37 degrees C. Kinetics of L-selectin shedding was similar in heparin and ACD, suggesting that cell loss did not derive from differences in cell activation. In comparison of buffy coat cell assay and whole blood assay, neutrophil CD11b expression was similar but background fluorescence was significantly higher in whole blood preparations. This implies that nonspecific antibody binding may occur more in whole blood assay, whereas in the buffy coat cell assay, sample manipulation procedures may slightly increase CD11b antibody binding, but not control antibody binding. Finally, it was confirmed that warming from 0 degrees C, but not from room temperature, to 37 degrees C increased CD11b expression significantly on neutrophils, and it was further shown that monocytes undergo similar changes. Cooling did not upregulate CD11b, and completely prevented LPS-induced upregulation. In conclusion, the results support use of ACD in evaluating CD11b expression; if EDTA is used, it is important to make sure that binding of CD11b antibody selected does not require presence of divalent cations in medium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665901     DOI: 10.1016/0022-1759(95)00105-j

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Analysis of the temperature affects on leukocyte surface antigen expression.

Authors:  Joel Jämsä; Virva Huotari; Eeva-Riitta Savolainen; Hannu Syrjälä; Tero Ala-Kokko
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

2.  Assessment of neutrophil function in patients with septic shock: comparison of methods.

Authors:  C Wenisch; P Fladerer; S Patruta; R Krause; W Hörl
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

3.  Comparison of sample fixation and the use of LDS-751 or anti-CD45 for leukocyte identification in mouse whole blood for flow cytometry.

Authors:  Melissa L Maes; Lisa B Davidson; Paul F McDonagh; Leslie S Ritter
Journal:  J Immunol Methods       Date:  2006-12-08       Impact factor: 2.303

4.  Expression of CD11b/CD18 adhesion molecules on circulating phagocytes-a novel aid to diagnose infection in patients with cancer.

Authors:  R Kallio; H Aalto; A Takala; P Ohtonen; J Collan; S Siitonen; H Joensuu; H Syrjala; H Repo
Journal:  Support Care Cancer       Date:  2008-04-15       Impact factor: 3.603

5.  The impact of delayed sample handling and type of anticoagulant on the interpretation of dysplastic signs detected by flow cytometry.

Authors:  Bettina Kárai; Zsófia Miltényi; Lajos Gergely; Marianna Száraz-Széles; János Kappelmayer; Zsuzsanna Hevessy
Journal:  Biochem Med (Zagreb)       Date:  2018-04-15       Impact factor: 2.313

6.  Comparison Between K3EDTA and Lithium Heparin as Anticoagulant to Isolate Bovine Granulocytes From Blood.

Authors:  Shima Hassan Baien; Melissa Natalie Langer; Maike Heppelmann; Maren von Köckritz-Blickwede; Nicole de Buhr
Journal:  Front Immunol       Date:  2018-07-11       Impact factor: 7.561

7.  Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.

Authors:  Minjun C Apodaca; Amy E Wright; Angela M Riggins; William P Harris; Raymond S Yeung; Lei Yu; Chihiro Morishima
Journal:  J Immunother Cancer       Date:  2019-08-28       Impact factor: 13.751

8.  Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels.

Authors:  Łukasz Sędek; Juan Flores-Montero; Alita van der Sluijs; Jan Kulis; Jeroen Te Marvelde; Jan Philippé; Sebastian Böttcher; Marieke Bitter; Joana Caetano; Vincent H J van der Velden; Edwin Sonneveld; Chiara Buracchi; Ana Helena Santos; Margarida Lima; Tomasz Szczepański; Jacques J M van Dongen; Alberto Orfao
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

9.  Optimization of methods for the accurate characterization of whole blood neutrophils.

Authors:  Ashley N Connelly; Richard P H Huijbregts; Harish C Pal; Valeriya Kuznetsova; Marcus D Davis; Krystle L Ong; Christian X Fay; Morgan E Greene; Edgar T Overton; Zdenek Hel
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.996

10.  Analysis of platelet-activating factors in severe sepsis by flow cytometry and its correlation with clinical sepsis scoring system: A pilot study.

Authors:  V Manu; Barun K Chakrabarty; Shivinder Singh
Journal:  Med J Armed Forces India       Date:  2018-10-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.